Predicting the Response of CML Patients to Tyrosine Kinase Inhibitor Therapy
Posted by rob on April 1, 2011 under Uncategorized | 
Comments are off for this article
Abstract As of 2011, the choice of tyrosine kinase inhibitor (TKI) for the patient with newly diagnosed chronic-phase chronic myelogenous
leukemia (CP-CML) is no longer limited to imatinib but can be expanded to include nilotinib and dasatinib. Since 2000, imatinib
has demonstrated remarkable efficacy in the majority of chronic-phase patients. Nilotinib and dasatinib, both more potent
TKIs, are likely to produce quicker and deeper molecular responses, but there are no established criteria for choosing the
best inhibitor for each patient. We now need to establish clearly defined recommendations to address this new stage, in which
individualized therapy in the front-line should become a reality. Likely to be paramount in this setting are assays that directly
assess the effic…
MedWorm Message: Find out about the Doctors 2.0 and You conference in Paris, June 22-23rd. The call is now on for posters and the start-up contest.